NewEdge Advisors LLC increased its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON – Free Report) by 32.4% during the 1st quarter, HoldingsChannel reports. The fund owned 5,315 shares of the biotechnology company’s stock after buying an additional 1,301 shares during the period. NewEdge Advisors LLC’s holdings in Axon Enterprise were worth $2,257,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of AXON. Brighton Jones LLC purchased a new position in shares of Axon Enterprise during the fourth quarter valued at approximately $480,000. Empowered Funds LLC grew its stake in shares of Axon Enterprise by 8.4% in the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock worth $1,067,000 after buying an additional 157 shares during the last quarter. Woodline Partners LP grew its stake in shares of Axon Enterprise by 40.6% in the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock worth $3,646,000 after buying an additional 2,003 shares during the last quarter. Sivia Capital Partners LLC bought a new position in Axon Enterprise during the 2nd quarter valued at approximately $284,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in Axon Enterprise during the 2nd quarter valued at approximately $3,467,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.
Insider Buying and Selling
In other Axon Enterprise news, President Joshua Isner sold 13,000 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $488.45, for a total value of $6,349,850.00. Following the transaction, the president owned 169,125 shares of the company’s stock, valued at approximately $82,609,106.25. This represents a 7.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $485.00, for a total value of $753,690.00. Following the completion of the transaction, the insider directly owned 34,024 shares in the company, valued at $16,501,640. The trade was a 4.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 68,989 shares of company stock valued at $36,016,932 over the last ninety days. 4.20% of the stock is owned by insiders.
Axon Enterprise Trading Down 0.4%
Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. The business had revenue of $904.39 million during the quarter, compared to analyst estimates of $876.42 million. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The company’s quarterly revenue was up 35.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.12 EPS. Research analysts expect that Axon Enterprise, Inc will post 1.63 earnings per share for the current year.
Wall Street Analysts Forecast Growth
AXON has been the topic of several analyst reports. Morgan Stanley boosted their target price on Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Citizens Jmp restated a “market outperform” rating and set a $700.00 price target on shares of Axon Enterprise in a report on Thursday, June 25th. Piper Sandler lifted their price target on Axon Enterprise from $724.00 to $732.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. upped their price target on shares of Axon Enterprise from $750.00 to $755.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, UBS Group raised their price objective on shares of Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $730.92.
View Our Latest Report on Axon Enterprise
Axon Enterprise Company Profile
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
Featured Stories
- Five stocks we like better than Axon Enterprise
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON – Free Report).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.
